Single CRISPR Dose Cuts Rare Swelling Attacks by 87% in Pivotal Trial
Intellia's in-vivo gene-editing therapy lonvo-z slashed hereditary angioedema attacks 87% vs placebo in a Phase 3 trial of 80 patients.
Summary
Intellia Therapeutics announced that a single dose of its CRISPR-based gene therapy, lonvo-z, reduced swelling attacks by 87% compared to placebo in patients with hereditary angioedema, a rare genetic disorder. In the 80-patient Phase 3 trial, over 60% of treated patients experienced zero attacks during the study period, versus just 11% on placebo. What makes this especially significant is that lonvo-z edits DNA directly inside the body — a first for CRISPR medicines. Intellia has already begun a rolling FDA submission. If approved, it would become only the second CRISPR-based medicine ever authorized, following Vertex's Casgevy for sickle cell disease, and the first to work through in vivo gene editing.
Detailed Summary
A landmark Phase 3 trial has shown that a single dose of a CRISPR-based gene therapy can dramatically reduce life-disrupting swelling attacks in patients with a rare but serious genetic condition. Intellia Therapeutics announced results for lonvo-z, its treatment for hereditary angioedema (HAE), a disorder caused by a genetic mutation that triggers unpredictable, potentially life-threatening swelling episodes throughout the body.
The trial enrolled 80 patients and demonstrated an 87% reduction in attack rates among those receiving lonvo-z compared to placebo. More strikingly, 60% of treated patients were completely attack-free during the study period, compared to only 11% in the placebo group. These are clinically meaningful numbers for a condition that currently requires ongoing preventive medications or on-demand treatments to manage.
What sets lonvo-z apart from existing therapies — and from the first approved CRISPR medicine, Vertex's Casgevy — is that it works in vivo, meaning it edits the patient's DNA directly inside the body rather than in cells removed and reintroduced in a lab. This approach could simplify treatment delivery and broaden the potential reach of gene editing therapies to conditions where ex vivo editing is impractical.
Intellia has already initiated a rolling submission with the FDA, signaling confidence in the data package and potentially accelerating the path to approval. If cleared, lonvo-z would represent a significant milestone: the first in vivo CRISPR therapy approved for human use, opening a new chapter for gene editing as a one-time curative strategy across a range of genetic diseases.
Caveats remain. The trial was relatively small at 80 patients, and long-term safety data for permanent in vivo DNA editing is still accumulating. Off-target editing effects and durability of response beyond the trial window will require continued monitoring in post-approval studies.
Key Findings
- Single dose of lonvo-z reduced hereditary angioedema attack rates by 87% vs placebo in Phase 3.
- Over 60% of treated patients had zero swelling attacks during the trial, vs 11% on placebo.
- Lonvo-z is the first CRISPR therapy to edit DNA directly inside the living body (in vivo).
- Intellia has begun rolling FDA submission, potentially setting up the second-ever approved CRISPR medicine.
- Long-term safety and durability of in vivo gene editing still require post-approval monitoring.
Methodology
This is a news report from STAT News, a credible specialized health and biotech journalism outlet. The findings are based on company-announced Phase 3 clinical trial results; full peer-reviewed publication has not yet been confirmed. Data has not been independently verified beyond the press release summary available in the article excerpt.
Study Limitations
The article is paywalled beyond the excerpt, limiting access to full trial methodology, safety data, and statistical details. The 80-patient sample is relatively small for a pivotal trial, and long-term follow-up data on permanent DNA editing safety is not yet available. Independent peer-reviewed publication of the full dataset should be reviewed before drawing firm conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.